TTR amyloidosis is increasingly recognized as a cause of diastolic heart failure and as much more common than previously thought. There are proven and investigational therapies that can slow or possibly stop this disease. In this interview, Rodney H. Falk, MD, FACC and Alison L. Bailey, MD FACC, with Jonathan R. Salik, MD, discuss Screening for Transthretin Amyloid Cardiomyopathy in Everyday Practice.